Analysts Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $9.33

Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.3333.

A number of analysts recently commented on SANA shares. Rodman & Renshaw began coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research report on Monday. Bank of America cut their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd.

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SANA. Rockefeller Capital Management L.P. raised its position in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after acquiring an additional 4,088 shares during the period. LRI Investments LLC purchased a new stake in shares of Sana Biotechnology in the 4th quarter worth $41,000. Walleye Capital LLC bought a new position in Sana Biotechnology in the 2nd quarter worth $35,000. Jacobi Capital Management LLC bought a new position in Sana Biotechnology in the 4th quarter worth $41,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Sana Biotechnology during the third quarter valued at $36,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Trading Down 1.7%

NASDAQ:SANA opened at $4.09 on Friday. The company has a market cap of $1.22 billion, a PE ratio of -5.38 and a beta of 2.16. The company has a 50 day simple moving average of $3.56 and a two-hundred day simple moving average of $3.41. Sana Biotechnology has a 12 month low of $2.61 and a 12 month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. Research analysts forecast that Sana Biotechnology will post -0.72 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.